Discover what's new.

Access the latest news, business developments, company updates, industry trends, events and more.

| By Caitlin Truesdale

Honors, promotions recognize CT bioscience talent

Craig M. Crews, the John C. Malone Professor of Molecular, Cellular, and Developmental Biology and Professor of Chemistry, Pharmacology, and Management at Yale University, together with...

| By Caitlin Truesdale

Weekly Roundup – May 19, 2022 

View this email in your browser Weekly Roundup – May 19, 2022                           AdvanceCT recently published the...

| By Caitlin Truesdale

Yale Innovation Summit notes thriving CT sector

With global markets continuing to slide, expect valuations to shrink and capital raises to get more difficult for the New Haven area’s bioscience companies, a...

| By Caitlin Truesdale

Bioasis and Neuramedy in license agreement

Bioasis, which is developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier, has entered into a research collaboration and license agreement...

| By Caitlin Truesdale

Bioais and Neuramedy in license agreement

Bioasis, which is developing its proprietary xB3TM platform technology for the delivery of therapeutics across the blood-brain barrier, has entered into a research collaboration and license agreement...

| By Caitlin Truesdale

CT Innovations invests in cannabis business

Connecticut Innovations recently invested $1.25 million in 1906, a recreational cannabis pills company moving its headquarters to the state. “CI’s investment is a major milestone...

| By Caitlin Truesdale

Sema4 completes acquisition of GeneDx

Sema4 has completed the acquisition of GeneDx. The transaction establishes Sema4 as one of the largest and most advanced providers of genomic testing in the U.S....

| By Caitlin Truesdale

Yale active in biotech as May summit approaches

Yale University’s Innovation Summit, which has become Yale’s largest entrepreneurship event and the largest gathering of venture capital investors in Connecticut, returns May 17-18 … more BioLabs, a...

| By Caitlin Truesdale

Weekly Roundup – May 12, 2022 

View this email in your browser Weekly Roundup – May 12, 2022                             ...

| By Caitlin Truesdale

FDA approves BMS Camzyos™ cardiomyopathy drug

The FDA has approved Camzyos™ from Bristol Myers Squibb (mavacamten for the treatment of adults with symptomatic New York Heart Association (NYHA) class II-III obstructive hypertrophic cardiomyopathy...